Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson(AbbVie (United States)), Andrew J. Souers(AbbVie (United States)), Chris Tse(AbbVie (United States)), Sha Jin(AbbVie (United States)), Erwin R. Boghaert(AbbVie (United States)), Nghi La, Darren C. Phillips(AbbVie (United States)), Kedar S. Vaidya(AbbVie (United States)), Daniel H. Albert(AbbVie (United States)), Xiao Yu(Huazhong Agricultural University), Xiaoju Max, Morey L. Smith(AbbVie (United States)), David C.S. Huang(Indonesia International Institute for Life Sciences), Wayne J. Fairbrother(Gene Therapy Laboratory), Terrance J. Magoc(AbbVie (United States)), Anatol Oleksijew(Abbott Fund), Deepak Sampath, Zhi‐Fu Tao(AbbVie (United States)), Michael Wendt(Abbott Fund), Lisa D. Belmont(Exelixis (United States)), Kym N. Lowes(The University of Melbourne), Le Wang(Rutgers, The State University of New Jersey), Jun Chen(Jiangsu Normal University), Haichao Zhang(Abbott Fund), Dolores Diaz, Stephen K. Tahir(Abbott Fund), Steven W. Elmore(AbbVie (United States)), Jacqueline M. Tarrant, John Xue(AbbVie (United States)), Saul H. Rosenberg(Abbott Fund), Peter Kovar(AbbVie (United States)), Michael J. Mitten(Abbott Fund), Paul Nimmer(Abbott Fund)
Cited by 541
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x <sub>L</sub> , but not Bcl-2, until displaced by BH3-only proteins
|Genes & Development|2005|1.2k
Bim: a novel member of the Bcl‐2 family that promotes apoptosis
|The EMBO Journal|1998|1.2k